# Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

> **NCT03199040** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- TNBC - Triple-Negative Breast Cancer
- Triple-negative Breast Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **BIOLOGICAL:** Neoantigen DNA vaccine
- **DEVICE:** TDS-IM system (Inchor Medical Systems)
- **PROCEDURE:** Peripheral blood draw

## Key facts

- **NCT ID:** NCT03199040
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-23
- **Primary completion:** 2022-11-21
- **Final completion:** 2023-05-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Drugs/equipment unavailable and insufficient funding
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199040, "Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03199040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*